X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/10/2860497/0/en/TILT-Biotherapeutics-Presents-Clinical-Data-on-TILT-123-in-Combination-with-KEYTRUDA-pembrolizumab-for-Ovarian-Cancer-at-AACR-2024.html
https://www.globenewswire.com//news-release/2024/02/14/2828826/0/en/TILT-Biotherapeutics-Awarded-USD-2M-Grant-from-US-Department-of-Defense-for-Ovarian-Cancer-Immunotherapy-Research.html
https://www.globenewswire.com//news-release/2023/12/08/2793021/0/en/TILT-Biotherapeutics-Announces-Positive-Clinical-Data-in-Checkpoint-Resistant-Metastatic-Melanoma-Phase-I-Trial-at-ESMO-Immuno-Oncology-2023.html
https://www.globenewswire.com//news-release/2023/11/06/2773739/0/en/TILT-Biotherapeutics-Announces-Positive-Clinical-Data-on-Lead-Asset-TILT-123-at-Society-for-Immunotherapy-of-Cancer-2023.html
https://www.clinicaltrialsarena.com/news/first-patient-dosed-in-tilt-123-phase-i-trial/
https://www.globenewswire.com/news-release/2023/05/15/2668374/0/en/TILT-Biotherapeutics-Announces-First-Patient-Dosed-in-Phase-I-Solid-Tumors-Trial-Assessing-Oncolytic-Adenovirus-TILT-123-in-Combination-with-Checkpoint-Inhibitor.html
https://www.pharmiweb.com/press-release/2022-10-11/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer
Market Place
Share 
